- Home
- HOLX vs INCY Comparison
HOLX vs INCY Comparison
Compare HOLX & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOLX
- INCY
- Stock Information
- Founded
- HOLX 1985
- INCY 1991
- Country
- HOLX United States
- INCY United States
- Employees
- HOLX N/A
- INCY N/A
- Industry
- HOLX Medical Electronics
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- HOLX Health Care
- INCY Health Care
- Exchange
- HOLX Nasdaq
- INCY Nasdaq
- Market Cap
- HOLX 16.5B
- INCY 17.0B
- IPO Year
- HOLX 1990
- INCY 1993
- Fundamental
- Price
- HOLX $74.10
- INCY $105.22
- Analyst Decision
- HOLX Hold
- INCY Buy
- Analyst Count
- HOLX 15
- INCY 19
- Target Price
- HOLX $79.00
- INCY $89.19
- AVG Volume (30 Days)
- HOLX 5.0M
- INCY 2.8M
- Earning Date
- HOLX 11-03-2025
- INCY 10-28-2025
- Dividend Yield
- HOLX N/A
- INCY N/A
- EPS Growth
- HOLX N/A
- INCY 3878.02
- EPS
- HOLX 2.49
- INCY 5.90
- Revenue
- HOLX $4,100,500,000.00
- INCY $4,813,105,000.00
- Revenue This Year
- HOLX $6.23
- INCY $19.33
- Revenue Next Year
- HOLX $5.37
- INCY $10.47
- P/E Ratio
- HOLX $29.76
- INCY $17.95
- Revenue Growth
- HOLX 1.74
- INCY 18.09
- 52 Week Low
- HOLX $51.90
- INCY $53.56
- 52 Week High
- HOLX $80.75
- INCY $106.47
- Technical
- Relative Strength Index (RSI)
- HOLX 70.04
- INCY 79.03
- Support Level
- HOLX $73.86
- INCY $91.16
- Resistance Level
- HOLX $74.28
- INCY $106.47
- Average True Range (ATR)
- HOLX 0.25
- INCY 4.10
- MACD
- HOLX -0.05
- INCY 1.59
- Stochastic Oscillator
- HOLX 29.07
- INCY 94.41
About HOLX Hologic Inc.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.